CR20230490A - Anti-cldn4/anti-cd137 bispecific antibody - Google Patents
Anti-cldn4/anti-cd137 bispecific antibodyInfo
- Publication number
- CR20230490A CR20230490A CR20230490A CR20230490A CR20230490A CR 20230490 A CR20230490 A CR 20230490A CR 20230490 A CR20230490 A CR 20230490A CR 20230490 A CR20230490 A CR 20230490A CR 20230490 A CR20230490 A CR 20230490A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cldn4
- bispecific antibody
- antibody
- binds
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 102100038447 Claudin-4 Human genes 0.000 abstract 2
- 101000882890 Homo sapiens Claudin-4 Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
The present invention addresses the problem of providing an anti-CLDN4/anti-CD137 bispecific antibody that can be used in treating cancer. This anti-CLDN4/anti-CD137 bispecific antibody, which is manufactured using an anti-CLDN4 antibody that binds to CLDN4 and an anti-CD137 antibody that binds to CD137, has an agonist action against CD137, promotes interferon-¿ production in T-cells, and demonstrates cytotoxic activity against cancer cells expressing CLDN4 on the cell surface. Furthermore, this anti-CLDN4/anti-CD137 bispecific antibody was able to be safely administered to monkeys. Accordingly, this anti-CLDN4/anti-CD137 bispecific antibody can be used to treat cancer in humans.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021072429 | 2021-04-22 | ||
PCT/JP2022/018350 WO2022224997A1 (en) | 2021-04-22 | 2022-04-21 | Anti-cldn4/anti-cd137 bispecific antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230490A true CR20230490A (en) | 2023-11-16 |
Family
ID=83722348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230490A CR20230490A (en) | 2021-04-22 | 2022-04-21 | Anti-cldn4/anti-cd137 bispecific antibody |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP4327823A1 (en) |
JP (2) | JP7365654B2 (en) |
KR (1) | KR20230171465A (en) |
CN (1) | CN117222672A (en) |
AR (1) | AR125398A1 (en) |
AU (1) | AU2022262542A1 (en) |
BR (1) | BR112023021950A2 (en) |
CA (1) | CA3217637A1 (en) |
CL (1) | CL2023003100A1 (en) |
CO (1) | CO2023015630A2 (en) |
CR (1) | CR20230490A (en) |
DO (1) | DOP2023000230A (en) |
EC (1) | ECSP23087918A (en) |
IL (1) | IL307744A (en) |
TW (1) | TW202309083A (en) |
WO (1) | WO2022224997A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023219120A1 (en) * | 2022-05-12 | 2023-11-16 | アステラス製薬株式会社 | Anti-cd37/anti-cd3 bispecific antibody |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
ES2616316T3 (en) | 2005-10-11 | 2017-06-12 | Amgen Research (Munich) Gmbh | Compositions comprising specific antibodies for different species and uses thereof |
WO2008011756A1 (en) | 2006-07-19 | 2008-01-31 | Jen-Shyan Chen | High power light emitting diode illuminating equipment with efficiently heat-dissipating module |
KR101826224B1 (en) | 2008-09-30 | 2018-02-06 | 아블렉시스, 엘엘씨 | Non-human mammals for the production of chimeric antibodies |
JP2014193853A (en) * | 2013-03-01 | 2014-10-09 | Japan Health Sciences Foundation | Antibody, fragment, pharmaceutical composition, molecule, and tumor marker |
WO2019048040A1 (en) * | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | Antibodies useful in cancer diagnosis |
WO2019135404A1 (en) * | 2018-01-05 | 2019-07-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
AU2019235900A1 (en) * | 2018-03-14 | 2020-08-13 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
CN112424229A (en) * | 2018-07-12 | 2021-02-26 | F星贝塔有限公司 | Antibody molecules that bind to CD137 and OX40 |
-
2022
- 2022-04-21 BR BR112023021950A patent/BR112023021950A2/en unknown
- 2022-04-21 KR KR1020237039211A patent/KR20230171465A/en unknown
- 2022-04-21 AR ARP220101032A patent/AR125398A1/en unknown
- 2022-04-21 EP EP22791768.9A patent/EP4327823A1/en active Pending
- 2022-04-21 CN CN202280029125.XA patent/CN117222672A/en active Pending
- 2022-04-21 JP JP2023515503A patent/JP7365654B2/en active Active
- 2022-04-21 CR CR20230490A patent/CR20230490A/en unknown
- 2022-04-21 WO PCT/JP2022/018350 patent/WO2022224997A1/en active Application Filing
- 2022-04-21 CA CA3217637A patent/CA3217637A1/en active Pending
- 2022-04-21 TW TW111115193A patent/TW202309083A/en unknown
- 2022-04-21 AU AU2022262542A patent/AU2022262542A1/en active Pending
- 2022-04-21 IL IL307744A patent/IL307744A/en unknown
-
2023
- 2023-09-29 JP JP2023169033A patent/JP2023182689A/en active Pending
- 2023-10-18 CL CL2023003100A patent/CL2023003100A1/en unknown
- 2023-10-19 DO DO2023000230A patent/DOP2023000230A/en unknown
- 2023-11-20 CO CONC2023/0015630A patent/CO2023015630A2/en unknown
- 2023-11-21 EC ECSENADI202387918A patent/ECSP23087918A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP23087918A (en) | 2023-12-29 |
CN117222672A (en) | 2023-12-12 |
JP7365654B2 (en) | 2023-10-20 |
AU2022262542A1 (en) | 2023-11-02 |
CL2023003100A1 (en) | 2024-03-22 |
DOP2023000230A (en) | 2023-12-15 |
EP4327823A1 (en) | 2024-02-28 |
BR112023021950A2 (en) | 2023-12-19 |
IL307744A (en) | 2023-12-01 |
TW202309083A (en) | 2023-03-01 |
AR125398A1 (en) | 2023-07-12 |
KR20230171465A (en) | 2023-12-20 |
JP2023182689A (en) | 2023-12-26 |
JPWO2022224997A1 (en) | 2022-10-27 |
CO2023015630A2 (en) | 2023-11-30 |
WO2022224997A1 (en) | 2022-10-27 |
CA3217637A1 (en) | 2022-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022013599A2 (en) | Anti-ccr8 antibodies for cancer treatment | |
CL2020002945A1 (en) | Methods for treating cancers and enhancing the efficacy of t-cell redirection therapeutics | |
MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
NZ765695A (en) | Immune cell organoid co-cultures | |
PH12019502661A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
EA202190421A1 (en) | MUSCLE-SPECIFIC COMPLEXES AND THEIR APPLICATION FOR TREATMENT OF MUSCLE ATROPHY | |
MX2021001284A (en) | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy. | |
PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
MX2019003886A (en) | Chimeric antigen receptors for the treatment of cancer. | |
MX360671B (en) | Pharmaceutical composition for treatment and/or prevention of cancer. | |
CL2008003449A1 (en) | Antibody or fragments thereof against the macrophage / rum stimulating protein receptor; pharmaceutical composition comprising it; use to inhibit angiogenesis, tumor growth, proliferation, migration and invasion of tumor cells, activation of rum or phosphorylation of mapk and / or akt; and use to treat cancer. | |
MX2021011816A (en) | Methods for production of car-nk cells and use thereof. | |
CR20230490A (en) | Anti-cldn4/anti-cd137 bispecific antibody | |
MX2022000726A (en) | Immunomodulatory antibodies and methods of use thereof. | |
MX2021015317A (en) | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein. | |
MX2021003567A (en) | Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder. | |
WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
MX2020002301A (en) | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer. | |
MX2021000505A (en) | Methods of treating cancer with tnf expressing myxoma virus. | |
BR112022021871A2 (en) | CAR POLYPEPTIDE, COMPOSITION, NUCLEIC ACID, IMMUNE CELL, METHOD FOR TREAT A TUMOR, AND, CELL BANK | |
WO2020212756A3 (en) | Reprogramming of polymorphonuclear leukocytes | |
MX2021001252A (en) | Immune modifying particles for the treatment of cancer. | |
MX2018009461A (en) | ANTIBODY-DRUG CONJUGATES TARGETING uPARAP. | |
MX2021013101A (en) | Anti-cd19 therapy in patients having a limited number of nk cells. |